In this report, the EMEA Cancer Treatment Drugs market is valued at USD XX million in 2019 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2019 and 2025.
Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K MT), revenue (Million USD), market share and growth rate of Cancer Treatment Drugs for these regions, from 2014 to 2025 (forecast)
Europe: Germany, France, UK, Russia, Italy and Benelux;
Middle East: Saudi Arabia, Israel, UAE and Iran;
Africa: South Africa, Nigeria, Egypt and Algeria.
EMEA Cancer Treatment Drugs market competition by top manufacturers/players, with Cancer Treatment Drugs sales volume (K MT), price (USD/MT), revenue (Million USD) and market share for each manufacturer/player; the top players including
Roche (Switzerland)
Novartis (Switzerland)
Celgene (U.S.)
Amgen (U.S.)
Johnson & Johnson (U.S.)
Bristol-Myers Squibb (U.S.)
Takeda (Japan)
Eli Lilly (U.S.)
Pfizer (U.S.)
AstraZeneca (Sweden)
Astellas (Japan)
Sanofi (France)
Bayer (Germany)
Merck & Co. (U.S.)
Biogen Idec (U.S.)
Kyowa Hakko Kirin (Japan)
Otsuka (Japan)
Teva (Israel)
Eisai (Japan)
Merck KGaA (Germany)
Ipsen (France)
AbbVie (U.S.)
Gilead Sciences (U.S.)
On the basis of product, this report displays the sales volume (K MT), revenue (Million USD), product price (USD/MT), market share and growth rate of each type, primarily split into
Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy (Biologic Therapy)
Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K MT), market share and growth rate of Cancer Treatment Drugs for each application, including
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Other Cancers
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
EMEA (Europe, Middle East and Africa) Cancer Treatment Drugs Market Report 2019
1 Cancer Treatment Drugs Overview
1.1 Product Overview and Scope of Cancer Treatment Drugs
1.2 Classification of Cancer Treatment Drugs
1.2.1 EMEA Cancer Treatment Drugs Market Size (Sales) Comparison by Type (2014-2024)
1.2.2 EMEA Cancer Treatment Drugs Market Size (Sales) Market Share by Type (Product Category) in 2018
1.2.3 Chemotherapy
1.2.4 Targeted Therapy
1.2.5 Immunotherapy
1.2.6 Hormonal Therapy (Biologic Therapy)
1.2.7 Others
1.3 EMEA Cancer Treatment Drugs Market by Application/End Users
1.3.1 EMEA Cancer Treatment Drugs Sales (Volume) and Market Share Comparison by Application (2014-2024
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Respiratory/Lung Cancer
1.3.7 Other Cancers
1.4 EMEA Cancer Treatment Drugs Market by Region
1.4.1 EMEA Cancer Treatment Drugs Market Size (Value) Comparison by Region (2014-2024)
1.4.2 Europe Status and Prospect (2014-2024)
1.4.3 Middle East Status and Prospect (2014-2024)
1.4.4 Africa Status and Prospect (2014-2024)
1.5 EMEA Market Size (Value and Volume) of Cancer Treatment Drugs (2014-2024)
1.5.1 EMEA Cancer Treatment Drugs Sales and Growth Rate (2014-2024)
1.5.2 EMEA Cancer Treatment Drugs Revenue and Growth Rate (2014-2024)
2 EMEA Cancer Treatment Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
2.1 EMEA Cancer Treatment Drugs Market Competition by Players/Manufacturers
2.1.1 EMEA Cancer Treatment Drugs Sales Volume and Market Share of Major Players (2014-2019)
2.1.2 EMEA Cancer Treatment Drugs Revenue and Share by Players (2014-2019)
2.1.3 EMEA Cancer Treatment Drugs Sale Price by Players (2014-2019)
2.2 EMEA Cancer Treatment Drugs (Volume and Value) by Type/Product Category
2.2.1 EMEA Cancer Treatment Drugs Sales and Market Share by Type (2014-2019)
2.2.2 EMEA Cancer Treatment Drugs Revenue and Market Share by Type (2014-2019)
2.2.3 EMEA Cancer Treatment Drugs Sale Price by Type (2014-2019)
2.3 EMEA Cancer Treatment Drugs (Volume) by Application
2.4 EMEA Cancer Treatment Drugs (Volume and Value) by Region
2.4.1 EMEA Cancer Treatment Drugs Sales and Market Share by Region (2014-2019)
2.4.2 EMEA Cancer Treatment Drugs Revenue and Market Share by Region (2014-2019)
2.4.3 EMEA Cancer Treatment Drugs Sales Price by Region (2014-2019)
3 Europe Cancer Treatment Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
3.1 Europe Cancer Treatment Drugs Sales and Value (2014-2019)
3.1.1 Europe Cancer Treatment Drugs Sales Volume and Growth Rate (2014-2019)
3.1.2 Europe Cancer Treatment Drugs Revenue and Growth Rate (2014-2019)
3.2 Europe Cancer Treatment Drugs Sales and Market Share by Type
3.3 Europe Cancer Treatment Drugs Sales and Market Share by Application
3.4 Europe Cancer Treatment Drugs Sales Volume and Value (Revenue) by Countries
3.4.1 Europe Cancer Treatment Drugs Sales Volume by Countries (2014-2019)
3.4.2 Europe Cancer Treatment Drugs Revenue by Countries (2014-2019)
3.4.3 Germany Cancer Treatment Drugs Sales and Growth Rate (2014-2019)
3.4.4 France Cancer Treatment Drugs Sales and Growth Rate (2014-2019)
3.4.5 UK Cancer Treatment Drugs Sales and Growth Rate (2014-2019)
3.4.6 Russia Cancer Treatment Drugs Sales and Growth Rate (2014-2019)
3.4.7 Italy Cancer Treatment Drugs Sales and Growth Rate (2014-2019)
3.4.8 Benelux Cancer Treatment Drugs Sales and Growth Rate (2014-2019)
4 Middle East Cancer Treatment Drugs (Volume, Value and Sales Price), by Region, Type and Application
4.1 Middle East Cancer Treatment Drugs Sales and Value (2014-2019)
4.1.1 Middle East Cancer Treatment Drugs Sales Volume and Growth Rate (2014-2019)
4.1.2 Middle East Cancer Treatment Drugs Revenue and Growth Rate (2014-2019)
4.2 Middle East Cancer Treatment Drugs Sales and Market Share by Type
4.3 Middle East Cancer Treatment Drugs Sales and Market Share by Application
4.4 Middle East Cancer Treatment Drugs Sales Volume and Value (Revenue) by Countries
4.4.1 Middle East Cancer Treatment Drugs Sales Volume by Countries (2014-2019)
4.4.2 Middle East Cancer Treatment Drugs Revenue by Countries (2014-2019)
4.4.3 Saudi Arabia Cancer Treatment Drugs Sales and Growth Rate (2014-2019)
4.4.4 Israel Cancer Treatment Drugs Sales and Growth Rate (2014-2019)
4.4.5 UAE Cancer Treatment Drugs Sales and Growth Rate (2014-2019)
4.4.6 Iran Cancer Treatment Drugs Sales and Growth Rate (2014-2019)
5 Africa Cancer Treatment Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
5.1 Africa Cancer Treatment Drugs Sales and Value (2014-2019)
5.1.1 Africa Cancer Treatment Drugs Sales Volume and Growth Rate (2014-2019)
5.1.2 Africa Cancer Treatment Drugs Revenue and Growth Rate (2014-2019)
5.2 Africa Cancer Treatment Drugs Sales and Market Share by Type
5.3 Africa Cancer Treatment Drugs Sales and Market Share by Application
5.4 Africa Cancer Treatment Drugs Sales Volume and Value (Revenue) by Countries
5.4.1 Africa Cancer Treatment Drugs Sales Volume by Countries (2014-2019)
5.4.2 Africa Cancer Treatment Drugs Revenue by Countries (2014-2019)
5.4.3 South Africa Cancer Treatment Drugs Sales and Growth Rate (2014-2019)
5.4.4 Nigeria Cancer Treatment Drugs Sales and Growth Rate (2014-2019)
5.4.5 Egypt Cancer Treatment Drugs Sales and Growth Rate (2014-2019)
5.4.6 Algeria Cancer Treatment Drugs Sales and Growth Rate (2014-2019)
6 EMEA Cancer Treatment Drugs Manufacturers/Players Profiles and Sales Data
6.1 Roche (Switzerland)
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Cancer Treatment Drugs Product Type, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Roche (Switzerland) Cancer Treatment Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
6.1.4 Main Business/Business Overview
6.2 Novartis (Switzerland)
6.2.1 Company Basic Information, Manufacturing Base and Competitors
6.2.2 Cancer Treatment Drugs Product Type, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Novartis (Switzerland) Cancer Treatment Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
6.2.4 Main Business/Business Overview
6.3 Celgene (U.S.)
6.3.1 Company Basic Information, Manufacturing Base and Competitors
6.3.2 Cancer Treatment Drugs Product Type, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Celgene (U.S.) Cancer Treatment Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
6.3.4 Main Business/Business Overview
6.4 Amgen (U.S.)
6.4.1 Company Basic Information, Manufacturing Base and Competitors
6.4.2 Cancer Treatment Drugs Product Type, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Amgen (U.S.) Cancer Treatment Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
6.4.4 Main Business/Business Overview
6.5 Johnson & Johnson (U.S.)
6.5.1 Company Basic Information, Manufacturing Base and Competitors
6.5.2 Cancer Treatment Drugs Product Type, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Johnson & Johnson (U.S.) Cancer Treatment Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
6.5.4 Main Business/Business Overview
6.6 Bristol-Myers Squibb (U.S.)
6.6.1 Company Basic Information, Manufacturing Base and Competitors
6.6.2 Cancer Treatment Drugs Product Type, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Bristol-Myers Squibb (U.S.) Cancer Treatment Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
6.6.4 Main Business/Business Overview
6.7 Takeda (Japan)
6.7.1 Company Basic Information, Manufacturing Base and Competitors
6.7.2 Cancer Treatment Drugs Product Type, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Takeda (Japan) Cancer Treatment Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
6.7.4 Main Business/Business Overview
6.8 Eli Lilly (U.S.)
6.8.1 Company Basic Information, Manufacturing Base and Competitors
6.8.2 Cancer Treatment Drugs Product Type, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Eli Lilly (U.S.) Cancer Treatment Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
6.8.4 Main Business/Business Overview
6.9 Pfizer (U.S.)
6.9.1 Company Basic Information, Manufacturing Base and Competitors
6.9.2 Cancer Treatment Drugs Product Type, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 Pfizer (U.S.) Cancer Treatment Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
6.9.4 Main Business/Business Overview
6.10 AstraZeneca (Sweden)
6.10.1 Company Basic Information, Manufacturing Base and Competitors
6.10.2 Cancer Treatment Drugs Product Type, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 AstraZeneca (Sweden) Cancer Treatment Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
6.10.4 Main Business/Business Overview
6.11 Astellas (Japan)
6.12 Sanofi (France)
6.13 Bayer (Germany)
6.14 Merck & Co. (U.S.)
6.15 Biogen Idec (U.S.)
6.16 Kyowa Hakko Kirin (Japan)
6.17 Otsuka (Japan)
6.18 Teva (Israel)
6.19 Eisai (Japan)
6.20 Merck KGaA (Germany)
6.21 Ipsen (France)
6.22 AbbVie (U.S.)
6.23 Gilead Sciences (U.S.)
7 Cancer Treatment Drugs Manufacturing Cost Analysis
7.1 Cancer Treatment Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Cancer Treatment Drugs
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Cancer Treatment Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Cancer Treatment Drugs Major Manufacturers in 2018
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 EMEA Cancer Treatment Drugs Market Forecast (2019-2024)
11.1 EMEA Cancer Treatment Drugs Sales, Revenue and Price Forecast (2019-2024)
11.1.1 EMEA Cancer Treatment Drugs Sales and Growth Rate Forecast (2019-2024)
11.1.2 EMEA Cancer Treatment Drugs Revenue and Growth Rate Forecast (2019-2024)
11.1.3 EMEA Cancer Treatment Drugs Price and Trend Forecast (2019-2024)
11.2 EMEA Cancer Treatment Drugs Sales, Revenue and Growth Rate Forecast by Region (2019-2024)
11.3 Europe Cancer Treatment Drugs Sales, Revenue and Growth Rate Forecast by Region (2019-2024)
11.4 Middle Eastt Cancer Treatment Drugs Sales, Revenue and Growth Rate Forecast by Region (2019-2024)
11.5 Africa Cancer Treatment Drugs Sales, Revenue and Growth Rate Forecast by Region (2019-2024)
11.6 EMEA Cancer Treatment Drugs Sales Forecast by Type (2019-2024)
11.7 EMEA Cancer Treatment Drugs Sales Forecast by Application (2019-2024)
12 Research Findings and Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
Request Discount 
Inquire Before Buy
